FFE 2013
Friday, April 3, 2026
26.9
C
Bengaluru
Hot topics
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
India’s Patent Revocations: Strengthening Access and Challenging Evergreening
The Indian Patent Office’s recent decision to revoke Novartis’...
Indian Pharma Market (IPM) Highlights – January 2025
Overall IPM Performance:
Monthly Growth: IPM monthly growth reached 8.4% in...
Are Digital Pharmacies a Game Changer?
Lower prices, discounts, convenience of ordering and home delivery are some of the benefits for consumers with e-pharmacies. The anonymity of the internet encourages patients to seek information about medicines that they would otherwise avoid. Mental health is one area where the consumers wish to maintain confidentiality and opt for online consultation and medication.
MedicinMan Steps into Year Five
Articles by K. Hariram, Daxesh Patel, Gopal Kishore, Amit Jain, Sunil Bajaj and Vivek Hattangadi
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Hot topics
How Trump’s Tariff War Could Affect India’s Top 25 Pharma Companies
April 14, 2025
India’s pharmaceutical industry, a global powerhouse, sends...
Pharma Marketing & The Reinvention
Introducing the top 10 companies in top 10 therapy areas according to statistics published by AIOCD
Making Peace with an Unlived Life – My Journey by Deep Bhandari
The Beginning
I was at crossroads after completing computer...
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
Newsletter
Get important news delivered directly to your inbox and stay connected!